Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.
about
Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMPPhase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteersNovel vaccine development strategies for inducing mucosal immunityModeling Influenza Virus Infection: A Roadmap for Influenza ResearchInduction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionStroke, dementia, and drug deliveryStable dry powder formulation for nasal delivery of anthrax vaccineMucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbitsMicroneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunityMucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motilityMucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challengeProtection from hemolytic uremic syndrome by eyedrop vaccination with modified enterohemorrhagic E. coli outer membrane vesiclesTransient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal deliveryEffective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection.Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection.Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.Oral immunization with Porphyromonas gingivalis outer membrane protein and CpGoligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity.Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I)Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination.Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunizationEnhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticlesDual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvantVaccination against Helicobacter pylori in non-human primate models and humans.TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccinesA bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity.Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.Vaccines against gonorrhea: current status and future challenges.A revisit of mucosal IgA immunity and oral tolerance.Influence of exogenous reproductive hormones on specific antibody production in genital secretions after vaginal vaccination with recombinant cholera toxin B subunit in humans.Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.Vibrio cholerae: lessons for mucosal vaccine design.A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulationsA Lipopolysaccharide from Pantoea Agglomerans Is a Promising Adjuvant for Sublingual Vaccines to Induce Systemic and Mucosal Immune Responses in Mice via TLR4 Pathway.Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses
P2860
Q21090975-9AFB6958-4A0B-43A1-9E68-BD84B3D6A3A3Q24545856-37F01469-A632-45D4-9A86-A899C7474CE7Q24607533-6774790F-830A-4B77-B660-9B6512550688Q26782421-3B16D16E-54D3-449E-BA45-0B83F048A82CQ27001897-62C8B6E8-680A-4D02-937F-B2A4F899E46FQ28166505-A6A9D938-70E6-4FD0-87CF-AFAA5502EC0CQ28386405-D3349031-E879-4CF1-BA52-4DFFAE835715Q28476839-51D4189A-F08D-426C-ABF2-CB42B67E9CD9Q30357830-D073B0F8-AC13-41EC-9D5E-308FCCE800A7Q30496874-CC0B38BF-C17C-48EA-A4E6-9E8301BE52CCQ33284583-26703ACF-69DD-4769-B524-13EC8119FFE7Q33416476-66580D5F-32FD-4D3C-9660-6ADBDDD94E73Q33503623-7786CB1B-D734-4777-BE57-AFC65940959FQ33584872-B00C3BAC-E310-4E0A-9173-ECB56B1931E4Q33665793-97553EC0-40F2-409A-89B3-3F1CA81BAF8EQ33717128-01A4FA1E-00DE-4BFA-AAAD-3B53A463F337Q33738499-DB5D8FC0-B0B4-4387-8C56-66771823D28CQ33768109-534E05B0-CF65-43ED-AF6F-61FBB2652069Q33870830-CED948E5-22C8-4427-B7B7-52D79D82A23FQ33909162-5522AC3A-03BB-47DE-AFBB-F3921D4C0BFFQ33909187-F7F32CEE-60A7-4193-8F90-DC5624BF4C7FQ34008022-8EE35E86-D404-4E43-ADB4-8BB3A2BA2B97Q34033764-64223B41-3FD0-443F-9191-9BEDD86B8A6FQ34119427-864AA9E4-6837-449A-BA91-16C765732E8BQ34130228-3CBFA4E8-6E3C-47DE-9138-803C3C105F8EQ34182385-BD1384BA-F9E2-467A-A529-C9763684CFA9Q34222750-5241C378-244F-4A47-9072-0F5C0AC903BDQ34290717-D29C6825-64E0-4924-AA95-1A839549FB7CQ34301259-4D57892C-DA18-427A-AC8E-159A6048BB34Q34357220-0D2CFF0E-94F8-4F0A-912B-853814886908Q34369729-E64B350D-EDB7-4F30-893C-E4B917746677Q34419871-CFB78E80-5D68-4051-8697-E33B10360AFCQ34429327-7B35E819-8609-4780-ADF3-2431A5E5EBEEQ34484116-A4A5EA8A-60AF-4918-8B58-F137CB4E1FFDQ34562952-1C4E3606-6A36-4CEC-8A3A-20906B4D139CQ34564412-CF17D899-565D-4E9B-BDD8-3E371B70C77CQ34641666-02CE8A7E-7660-4CB2-A36E-6354A43D05D4Q34669830-48C3E88D-D695-4751-AC4F-A98C6DE9307CQ34761746-AA81AA93-FAEE-49F3-A26B-9E183E154213Q34852816-2A7B8708-DB0B-4853-B2EA-F1C938D9A29F
P2860
Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Cutting edge: the mucosal adju ...... oteins into olfactory tissues.
@en
type
label
Cutting edge: the mucosal adju ...... oteins into olfactory tissues.
@en
prefLabel
Cutting edge: the mucosal adju ...... oteins into olfactory tissues.
@en
P2093
P1476
Cutting edge: the mucosal adju ...... oteins into olfactory tissues.
@en
P2093
P304
P356
10.4049/JIMMUNOL.165.9.4778
P407
P577
2000-11-01T00:00:00Z